Autolus Therapeutics Appoints Ryan Richardson to Board

Autolus Therapeutics ( (AUTL) ) has shared an update.

On December 1, 2025, Autolus Therapeutics announced the appointment of Ryan Richardson as a Class I director on its Board of Directors. Mr. Richardson, who has over 20 years of experience in healthcare and investment banking, previously served as Chief Strategy Officer at BioNTech SE, where he played a significant role in the company’s global expansion and transition to a commercial stage. His expertise is expected to aid Autolus in its growth as a commercial-stage company, particularly in expanding the reach of its therapy, obe-cel, in new indications.

The most recent analyst rating on (AUTL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.

Spark’s Take on AUTL Stock

According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.

Autolus Therapeutics faces significant financial challenges with ongoing losses and negative cash flows, impacting its overall score. While technical indicators suggest a bearish trend, the company has shown strong market penetration and is well-capitalized, providing some support for future growth.

To see Spark’s full report on AUTL stock, click here.

More about Autolus Therapeutics

Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation programmed T cell therapies for cancer and autoimmune diseases. The company utilizes proprietary T cell programming technologies to engineer therapies aimed at better recognizing and eliminating target cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates targeting hematological malignancies, solid tumors, and autoimmune diseases.

Average Trading Volume: 3,928,661

Technical Sentiment Signal: Sell

Current Market Cap: $367.3M

Learn more about AUTL stock on TipRanks’ Stock Analysis page.